Showing results (151-160 of 217) with videos related to

Sort By:
Pageof 22
Arthritis Care & Research|April 19, 2022
Impact of Belimumab on Organ Damage in Systemic Lupus ErythematosusMurray B Urowitz, Cynthia Aranow, Yumi Asukai, et al.
Annals of the Rheumatic Diseases|April 30, 2015
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locusJohn Bowes, Sabine Loehr, Ashley Budu-Aggrey, et al.
Cytokine|May 4, 2021
Differential levels of IFNα subtypes in autoimmunity and viral infectionVincent Bondet, Mathieu P Rodero, Céline Posseme, et al.
Ebiomedicine|November 13, 2022
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunityJames I Robinson, Md Yuzaiful Md Yusof, Vinny Davies, et al.
Annals of the Rheumatic Diseases|August 19, 2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE studyCynthia Aranow, Cornelia F Allaart, Zahir Amoura, et al.
Lupus Science & Medicine|September 23, 2025
Towards a minimal core dataset for systemic lupus erythematosus studiesStephen McDonald, Jialin Teng, Chengde Yang, et al.
Arthritis and Rheumatism|February 13, 2013
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitisMaria Apel, Steffen Uebe, John Bowes, et al.
Lupus Science & Medicine|February 10, 2021
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and researchKarin Tse, Sanjyot Sangodkar, Lauren Bloch, et al.
Nature Genetics|October 19, 2010
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasisUlrike Hüffmeier, Steffen Uebe, Arif B Ekici, et al.
Annals of the Rheumatic Diseases|February 3, 2022
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndromeGeorge C Drosos, Daisy Vedder, Eline Houben, et al.
Pageof 22